Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 58

    1.

    An auto-SCT-based total therapy resulted in encouraging outcomes in adolescents and young adults with acute lymphoblastic leukemia: report from a single center of China.

    Huang J, Zou DH, Li ZJ, Fu MW, Xu Y, Zhao YZ, Qi JY, Feng SZ, Liu BC, Lin D, Mi YC, Han MZ, Wang JX, Qiu LG.

    Bone Marrow Transplant. 2011 Dec 19. doi: 10.1038/bmt.2011.220. [Epub ahead of print]

    PMID:
    22179555
    [PubMed - as supplied by publisher]
    2.

    Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis.

    Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Zhang XH, Chen YH, Han W, Wang FR, Wang JZ, Yan CH, Huang XJ.

    Bone Marrow Transplant. 2011 Nov 7. doi: 10.1038/bmt.2011.213. [Epub ahead of print]

    PMID:
    22056641
    [PubMed - as supplied by publisher]
    3.

    Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia.

    Chiusolo P, Metafuni E, Bellesi S, Giammarco S, Za T, Laurenti L, Sorà F, Leone G, Sica S.

    Bone Marrow Transplant. 2011 Sep 19. doi: 10.1038/bmt.2011.183. [Epub ahead of print] No abstract available.

    PMID:
    21927035
    [PubMed - as supplied by publisher]
    4.

    Error occurred: cannot get document summary

    PMID:
    21897399

    5.

    Risks and benefits of ovarian shielding in female patients undergoing TBI: a decision analysis.

    Kanda Y, Sakamoto K, Ashizawa M, Sato M, Terasako K, Kikuchi M, Kimura SI, Okuda S, Kako S, Oshima K.

    Bone Marrow Transplant. 2011 Aug;46(8):1145-7. doi: 10.1038/bmt.2010.240. Epub 2010 Oct 11. No abstract available.

    PMID:
    20935682
    [PubMed - indexed for MEDLINE]
    6.

    Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.

    Bokhari SW, Watson L, Nagra S, Cook M, Byrne JL, Craddock C, Russell NH.

    Bone Marrow Transplant. 2012 Apr;47(4):528-34. doi: 10.1038/bmt.2011.138. Epub 2011 Jul 11.

    PMID:
    21743502
    [PubMed - in process]
    7.

    Current status of allogeneic HST for chronic myelomonocytic leukemia.

    Cheng H, Kirtani VG, Gergis U.

    Bone Marrow Transplant. 2012 Apr;47(4):535-41. doi: 10.1038/bmt.2011.141. Epub 2011 Jul 11.

    PMID:
    21743499
    [PubMed - in process]
    8.

    Extramedullary relapse following allogeneic BMT in a postpartum female patient with acute lymphoblastic leukemia.

    He X, Wu D, Sun A.

    Bone Marrow Transplant. 2012 Apr;47(4):598-9. doi: 10.1038/bmt.2011.123. Epub 2011 Jul 4. No abstract available.

    PMID:
    21725371
    [PubMed - in process]
    9.

    Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT.

    Zhao XS, Jin S, Zhu HH, Xu LP, Liu DH, Chen H, Liu KY, Huang XJ.

    Bone Marrow Transplant. 2012 Apr;47(4):499-507. doi: 10.1038/bmt.2011.121. Epub 2011 Jun 6.

    PMID:
    21643023
    [PubMed - in process]
    10.

    Renal failure in multiple myeloma: a medical emergency.

    Wirk B.

    Bone Marrow Transplant. 2011 Jun;46(6):771-83. doi: 10.1038/bmt.2011.8. Epub 2011 Feb 21. Review.

    PMID:
    21339749
    [PubMed - indexed for MEDLINE]
    11.

    Prevalence of osteonecrosis and associated risk factors in children before allogeneic BMT.

    Sharma S, Yang S, Rochester R, Britton L, Leung WH, Yang J, Neel MD, Ness KK, Kaste SC.

    Bone Marrow Transplant. 2011 Jun;46(6):813-9. doi: 10.1038/bmt.2010.210. Epub 2010 Sep 6.

    PMID:
    20818446
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    12.

    CT60 single-nucleotide polymorphism as a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia.

    Metaxas Y, Bertz H, Spyridonidis A, Spyroupoulou-Vlachou M, Porzelius C, Finke J.

    Bone Marrow Transplant. 2012 Mar;47(3):411-5. doi: 10.1038/bmt.2011.101. Epub 2011 May 9.

    PMID:
    21552305
    [PubMed - in process]
    13.

    Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution.

    Martino R, Kerguelen A, Valcárcel D, Sureda A, Fachini L, Piñana JL, Briones J, Delgado J, Brunet S, Sierra J.

    Bone Marrow Transplant. 2011 May;46(5):690-701. Epub 2010 Sep 6.

    PMID:
    20818448
    [PubMed - indexed for MEDLINE]
    14.

    Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.

    Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Field T, Perkins J, Ayala E, Perez L, Fernandez H.

    Bone Marrow Transplant. 2011 May;46(5):641-9. Epub 2010 Aug 16.

    PMID:
    20711242
    [PubMed - indexed for MEDLINE]
    15.

    Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.

    Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M, Reynolds C, Liney D, Kao G, Ho V, Armand P, Koreth J, Alyea E, Dey BR, Attar E, Spitzer T, Boussiotis VA, Ritz J, Soiffer R, Antin JH, Ballen K.

    Bone Marrow Transplant. 2011 May;46(5):659-67. Epub 2010 Aug 9.

    PMID:
    20697368
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    16.

    High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML.

    O'Meara A, Pabst T, Heim D, Gerull S, Bucher C, Halter J, Arber C, Rovò A, Tichelli A, Gratwohl A, Stern M.

    Bone Marrow Transplant. 2011 May;46(5):636-40. Epub 2010 Aug 9.

    PMID:
    20697364
    [PubMed - indexed for MEDLINE]
    17.

    GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome.

    Alsultan A, Giller RH, Gao D, Bathurst J, Hild E, Gore L, Foreman NK, Keating A, Quinones RR.

    Bone Marrow Transplant. 2011 May;46(5):668-75. Epub 2010 Aug 2.

    PMID:
    20676147
    [PubMed - indexed for MEDLINE]
    18.

    Toll-like receptor 9, NOD2 and IL23R gene polymorphisms influenced outcome in AML patients transplanted from HLA-identical sibling donors.

    Elmaagacli AH, Steckel N, Ditschkowski M, Hegerfeldt Y, Ottinger H, Trenschel R, Koldehoff M, Beelen DW.

    Bone Marrow Transplant. 2011 May;46(5):702-8. Epub 2010 Jul 12.

    PMID:
    20622911
    [PubMed - indexed for MEDLINE]
    19.

    Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.

    Mahindra A, Bolwell BJ, Rybicki L, Elder P, Kalaycio M, Dean R, Avalos B, Sobecks R, Tench S, Andresen S, Pohlman B, Sweetenham J, Devine S, Copelan E.

    Bone Marrow Transplant. 2012 Feb;47(2):231-5. doi: 10.1038/bmt.2011.73. Epub 2011 Apr 4.

    PMID:
    21460870
    [PubMed - in process]
    20.

    Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation.

    Khabori MA, El-Emary M, Xu W, Guyatt G, Galal A, Kuruvilla J, Lipton J, Messner H, Gupta V.

    Bone Marrow Transplant. 2011 Apr;46(4):516-22. Epub 2010 Jul 12.

    PMID:
    20622907
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk